On Monday, Shares of Gilead Sciences Inc. (NASDAQ:GILD), lost -2.03% to $110.54.
Gilead Sciences declared the promotion of William Lee, PhD to Executive Vice President, Research, and Brett Pletcher to Executive Vice President and General Counsel. Dr. Lee and Mr. Pletcher will both join Gilead’s senior leadership committee.
Dr. Lee joined Gilead in 1991 and was promoted to Senior Vice President, Research in 2000. He has led the expansion of the company’s research activities across a range of therapeutic areas, counting HIV, liver diseases, hematology/oncology, inflammation and respiratory diseases and cardiovascular conditions. He reports to Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer. Preceding to joining Gilead, Dr. Lee worked at California Biotechnology, Inc. and Syntex. He received his BS in Chemistry from the University of Massachusetts, PhD in Chemistry from the University of California at San Diego and did postdoctoral work at the Ecole Polytech Federal Lausanne and the University of California at Santa Barbara.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific.
Shares of Huntington Bancshares Incorporated (NASDAQ:HBAN), declined -1.36% to $11.60, during its last trading session.
Huntington Bancshares Incorporated declared the release of its mid-cycle, company-run capital stress test results as required by the Dodd-Frank Act. Results can be found on Huntington’s Investor Relations website under the heading “Publications and Filings” (http://huntington-ir.com/main/Regulatory.htm). Results are based on a forward-looking exercise using hypothetical severely adverse macroeconomic assumptions developed by Huntington.
Huntington Bancshares Incorporated operates as a holding company for The Huntington National Bank that provides commercial, small business, consumer, and mortgage banking services.
Finally, Ballard Power Systems Inc. (NASDAQ:BLDP), ended its last trade with -6.94% loss, and closed at $1.34.
Ballard Power Systems declared that it has signed a contract to provide a 1 megawatt (1MW) ClearGen™ fuel cell distributed generation system for Hydrogène de France (HDF) which will be deployed at an AkzoNobel (www.akzonobel.com) sodium chlorate chemical plant in Bordeaux Métropole, France . In addition, Ballard will provide engineering services support for the program.
Kevin Colbow , Ballard’s Vice President, Technology Solutions said, “This Technology Solutions transaction is another demonstration of Ballard’s competency in addressing customer needs in a variety of application areas. This program will benefit from our experience with the one megawatt ClearGen™ system that has been successfully operating to provide peak power at Toyota’s Torrance California campus over the last two years.”
Powered by its proprietary proton exchange membrane (PEM) fuel cells, the Ballard ClearGen™ clean energy system will enable HDF to generate electricity and supply it to the local grid, assisting satisfy local power demands.
Ballard Power Systems Inc. engages in the development and commercialization of proton exchange membrane fuel cells worldwide. The company is primarily involved in the design, development, manufacture, sale, and service of fuel cell stacks, modules, and systems for various applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
